Published in Oncogenesis on April 16, 2012
A comprehensive phylogenetic and structural analysis of the carcinoembryonic antigen (CEA) gene family. Genome Biol Evol (2014) 0.83
The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. Histochem Cell Biol (2016) 0.80
Glycosylation Alters Dimerization Properties of a Cell-surface Signaling Protein, Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1). J Biol Chem (2016) 0.75
Loss of CEACAM1, a Tumor-Associated Factor, Attenuates Post-infarction Cardiac Remodeling by Inhibiting Apoptosis. Sci Rep (2016) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res (2004) 9.70
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A (2002) 3.11
CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol (2006) 2.13
Cellular senescence: hot or what? Curr Opin Genet Dev (2009) 1.68
Oncogene-induced senescence: the bright and dark side of the response. Curr Opin Cell Biol (2010) 1.58
Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nat Immunol (2001) 1.51
Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog (1998) 1.42
DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem (2007) 1.37
Dissection of a DNA-damage-induced transcriptional network using a combination of microarrays, RNA interference and computational promoter analysis. Genome Biol (2005) 1.31
Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue. Oncogene (2006) 1.29
Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene (2006) 1.21
Tumor suppressive role of a 2.4 Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene (2005) 1.08
Impaired lymphocyte development and function in Clast5/Stra13/DEC1-transgenic mice. Eur J Immunol (2004) 0.98
Regulation of CEACAM1 transcription in human breast epithelial cells. BMC Mol Biol (2010) 0.92
Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells. J Biol Chem (2010) 0.89
Gamma-radiolysis study of the reductive activation of neocarzinostatin by the carboxyl radical. Biochimie (1984) 0.89
[CEACAM1 as a central modulator of metabolism, tumor progression, angiogenesis and immunity]. Med Sci (Paris) (2009) 0.80
Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res (1999) 12.83
Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 3.84
Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature (2000) 2.57
Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol (1996) 2.42
A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev (1995) 2.33
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev (2000) 2.19
A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med (2000) 2.17
Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother (1996) 2.14
The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol (2008) 2.08
Simple decompression or subcutaneous anterior transposition of the ulnar nerve for cubital tunnel syndrome. J Hand Surg Br (2005) 1.96
The transcription factor RFX3 directs nodal cilium development and left-right asymmetry specification. Mol Cell Biol (2004) 1.87
A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet (1998) 1.84
RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res (1996) 1.71
Stent-assisted mechanical recanalization for treatment of acute intracerebral artery occlusions. Stroke (2010) 1.69
Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency. N Engl J Med (1997) 1.60
Revascularization in acute ischaemic stroke using the penumbra system: the first single center experience. Eur J Neurol (2009) 1.59
Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene (1998) 1.51
Comparison of stent free cell area and cerebral lesions after unprotected carotid artery stent placement. Eur J Vasc Endovasc Surg (2011) 1.51
Mobile stroke unit for diagnosis-based triage of persons with suspected stroke. Neurology (2012) 1.49
RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer. Mol Cell Biol (1993) 1.46
Induction of HLA class II genes by IFN-gamma is transcriptional and requires a trans-acting protein. J Immunol (1989) 1.46
Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med (1994) 1.46
RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J (1997) 1.45
A practice audit of oral contraceptive users. Br Med J (Clin Res Ed) (1983) 1.44
Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med (2001) 1.40
Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol (1998) 1.40
Cloning and functional characterization of mammalian homologues of the COPII component Sec23. Mol Biol Cell (1996) 1.39
CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. Mol Cell Biol (2000) 1.39
A consensus motif in the RFX DNA binding domain and binding domain mutants with altered specificity. Mol Cell Biol (1996) 1.37
Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med (2001) 1.32
Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood (1998) 1.32
Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX. Mol Cell Biol (1994) 1.30
Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev (2000) 1.23
Two DNA-binding proteins discriminate between the promoters of different members of the major histocompatibility complex class II multigene family. Mol Cell Biol (1990) 1.22
Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem (1999) 1.22
Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy. Am J Hum Genet (2006) 1.21
A deficiency in RFX3 causes hydrocephalus associated with abnormal differentiation of ependymal cells. Eur J Neurosci (2006) 1.21
Endovascular treatment of brain arteriovenous malformations using a liquid embolic agent: results of a prospective, multicentre study (BRAVO). Eur Radiol (2013) 1.19
Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Tissue Antigens (2006) 1.18
Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp Cell Res (1998) 1.14
MHC class II-deficient combined immunodeficiency: a disease of gene regulation. Immunol Rev (1994) 1.14
Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J Immunol (1995) 1.13
Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther (2001) 1.13
Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity (1998) 1.12
Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. Eur J Immunol (1998) 1.11
Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res (1996) 1.11
Simultaneous assessment of cerebral hemodynamics and contrast agent uptake in lesions with disrupted blood-brain-barrier. Magn Reson Imaging (1999) 1.09
Dimeric RFX proteins contribute to the activity and lineage specificity of the interleukin-5 receptor alpha promoter through activation and repression domains. Mol Cell Biol (1999) 1.09
Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein (1996) 1.09
A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y. Mol Cell Biol (2000) 1.06
The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters. Mol Cell Biol (1992) 1.05
Organization and sequence analysis of a cluster of repetitive DNA elements from Xenopus laevis. J Mol Biol (1981) 1.04
Time course of the apparent diffusion coefficient after cerebral infarction. Eur Radiol (2002) 1.01
Structure of the oxygen adduct intermediate in the bacterial luciferase reaction: C nuclear magnetic resonance determination. Proc Natl Acad Sci U S A (1978) 1.00
Regulation of VEGF and VEGF receptor expression in the rodent mammary gland during pregnancy, lactation, and involution. Dev Dyn (2000) 0.99
Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur J Immunol (2000) 0.97
Decompressive craniectomy in a rat model of "malignant" cerebral hemispheric stroke: experimental support for an aggressive therapeutic approach. J Neurosurg (1996) 0.97
Dissection of functional NF-Y-RFX cooperative interactions on the MHC class II Ea promoter. J Mol Biol (2000) 0.97
On the mechanism of reductive activation in the mode of action of some anticancer drugs. Biochimie (1982) 0.96
Decompressive craniectomy for cerebral infarction. An experimental study in rats. Stroke (1995) 0.96
Cognitive changes after carotid artery stenting. Neuroradiology (2006) 0.96
Regulatory factor-X binding to mutant HLA-DRA promoter sequences. Nucleic Acids Res (1991) 0.96
Multifocal Signal Loss at Bridging Veins on Susceptibility-Weighted Imaging in Abusive Head Trauma. Clin Neuroradiol (2014) 0.95
Angiogenesis-regulating cytokines: activities and interactions. Curr Top Microbiol Immunol (1996) 0.95
Molecular genetics of the Bare lymphocyte syndrome. Rev Immunogenet (2000) 0.95
Primary immunodeficiency mutation databases. Adv Genet (2001) 0.95
Biological basis for chemo-radiotherapy interactions. Eur J Cancer (2002) 0.95
MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore) (2001) 0.94
Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene. Mol Cell Biol (1989) 0.94
The different level of expression of HLA-DRB1 and -DRB3 genes is controlled by conserved isotypic differences in promoter sequence. Hum Immunol (1993) 0.94
S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer (1995) 0.93
Frequency of development of early cortical scarring in acute primary pyelonephritis. Kidney Int (1989) 0.92
Hyperperfusion syndrome after carotid stent angioplasty. Neuroradiology (2008) 0.92
Clathrin-coated pit-mediated receptor internalization. Role of internalization signals and receptor mobility. J Biol Chem (1993) 0.92
Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res (1994) 0.92
Vascular endothelial growth factor is increased in devascularized rat islets of Langerhans in vitro. Transplantation (1997) 0.91
Peri-interventional Subarachnoid Hemorrhage During Mechanical Thrombectomy with stent retrievers in Acute Stroke: A Retrospective Case-Control Study. Clin Neuroradiol (2014) 0.90
Delayed vascular injury after single high-dose irradiation in the rat brain: histologic immunohistochemical, and angiographic studies. Radiology (1999) 0.90
Localization of the two protease binding sites in human alpha 2-macroglobulin. J Biol Chem (1981) 0.90
Spiral CT vs incremental CT: is spiral CT superior in imaging of the brain? Eur Radiol (1998) 0.90
A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors. J Leukoc Biol (2001) 0.90
Thalamic volumes in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2010) 0.89
[Vascular anomalies of the cerebellopontine angle]. Radiologe (2006) 0.89
The seven-stranded beta-barrel structure of apo-neocarzinostatin as compared to the immunoglobulin domain. Biochimie (1993) 0.89
Gamma-radiolysis study of the reductive activation of neocarzinostatin by the carboxyl radical. Biochimie (1984) 0.89
Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol Cell Biol (2001) 0.89
Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis. J Cell Sci (1997) 0.88
Filling a cervical spine cage with local autograft: change of bone density and assessment of bony fusion. Zentralbl Neurochir (2006) 0.88
CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes. Int Immunol (1999) 0.88
Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro. Br J Cancer (2004) 0.88
Study of the Hansenula anomala yeast flavocytochrome-b2-cytochrome-c complex 2. Localization of the main association area. Eur J Biochem (1983) 0.87
Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation. Int J Radiat Biol (2000) 0.87
Structural analysis of a cDNA clone from Xenopus laevis containing a repetitive sequence element. Dev Biol (1982) 0.86
A comparison of 2 stroke devices: the new Aperio clot-removal device and the solitaire AB/FR. AJNR Am J Neuroradiol (2012) 0.86
Three-dimensional solution structure of apo-neocarzinostatin from Streptomyces carzinostaticus determined by NMR spectroscopy. Eur J Biochem (1992) 0.86
Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B. Immunogenetics (2000) 0.86
DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res (1993) 0.86
Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage (2009) 0.85
Atheromatous renal disease. Am J Med (1988) 0.85